Arial en es it fr

Categoria

Arial Marchi, Arial Analoghi

Arial Marchi miscela

  • Advair 100 Diskus (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 125 (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 250 (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 250 Diskus (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 500 Diskus (Fluticasone Propionate + Salmeterol Xinafoate)
  • Arial Formula chimica

    C25H37NO4

    Arial RX link

    http://www.rxlist.com/cgi/generic/salmeterol.htm

    Arial FDA foglio

    Arial FDA

    Arial DMS (foglio di materiale di sicurezza)

    Arial MSDS

    Arial Sintesi di riferimento

    Skidmore SE et al. US Pat. 4.992.474 (1991).

    Arial Peso molecolare

    415.566 g/mol

    Arial Temperatura di fusione

    75.5-76.5 oC

    Arial H2O Solubilita

    Scarsamente solubile

    Arial Stato

    Solid

    Arial LogP

    5.022

    Arial Forme di dosaggio

    Dosato (aerosol); Polvere

    Arial Indicazione

    Per il trattamento di asma e broncopneumopatia cronica ostruttiva (BPCO).

    Arial Farmacologia

    Salmeterolo è una lunga durata d'azione beta2-adrenergici agonisti (LABA), di solito solo prescritto per l'asma grave persistente dopo precedente trattamento con una breve durata d'azione beta-agonista come il salbutamolo e è prescritto in concomitanza con un corticosteroide, come beclometasone. La principale differenza notevole di salmeterolo a salbutamolo è che la durata d'azione dura circa 12 ore a confronto con 4-6 ore di salbutamolo. Se usato regolarmente ogni giorno come presecribed, salmeterolo per via inalatoria riduce il numero e la gravità degli attacchi di asma. Tuttavia, non è per l'uso per alleviare un attacco d'asma che ha già iniziato. Salmeterolo per via inalatoria funziona come altri beta 2-agonisti, causando broncodilatazione rilassando la muscolatura liscia delle vie aeree in modo da trattare l'esacerbazione dell'asma. Salmeterolo è simile in azione a formoterolo, tuttavia formoterolo ha dimostrato di avere una maggiore rapidità di azione di salmeterolo in conseguenza di una minore lipofilia, ed è stato anche dimostrato di essere più potente - di 12 mg di dose di formoterolo è stato dimostrato essere equivalente a una dose di 50 mcg di salmeterolo.

    Arial Assorbimento

    A causa della piccola dose terapeutica, i livelli sistemici di salmeterolo sono bassi o non rilevabili dopo inalazione di dosi raccomandate.

    Arial Tossicita

    Sintomi di sovradosaggio includono angina (dolore al petto), vertigini, secchezza delle fauci, affaticamento, sintomi simil-influenzali, mal di testa, irregolarità cardiaca, pressione sanguigna alta o bassa, glicemia alta, insonnia, crampi muscolari, nausea, nervosismo, tachicardia, convulsioni e tremori. Per via orale, non si sono verificati decessi in ratti a 1.000 mg / kg (circa 81.000 volte la dose massima raccomandata inalazione al giorno negli adulti e circa 38.000 volte la dose massima giornaliera raccomandata inalazione in bambini su una base mg/m2).

    Arial Informazioni paziente

    PATIENT INFORMATION

    Patients being treated with SEREVENT DISKUS should receive the following information and instructions. This information is
    intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or
    intended effects.

    It is important that patients understand how to use the DISKUS appropriately and how to use SEREVENT DISKUS in relation to
    other asthma or COPD medications they are taking. Patients should be given the following information:

    1. The action of SEREVENT DISKUS may last up to 12 hours or longer. The recommended dosage (1 inhalation twice daily, morning
    and evening) should not be exceeded.

    2. Most patients are able to taste or feel a dose delivered from SEREVENT DISKUS. However, whether or not patients are able to
    sense delivery of a dose, you should instruct them not to exceed the recommended dose of 1 inhalation twice daily, morning and
    evening. You should instruct them to contact you or the pharmacist if they have questions.

    3. SEREVENT DISKUS is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.
    Acute symptoms should be treated with an inhaled, short-acting bronchodilator (the physician should provide the patient with
    such medication and instruct the patient in how it should be used).

    4. Patients should not stop therapy with SEREVENT DISKUS for asthma or COPD without physician/provider guidance since symptoms
    may worsen after discontinuation.

    5. When used for the treatment of EIB, 1 inhalation of SEREVENT DISKUS should be taken 30 minutes before exercise.

    Additional doses of SEREVENT should not be used for 12 hours.

    Patients who are receiving SEREVENT DISKUS twice daily should not use additional SEREVENT for prevention of EIB.

    6. The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously
    worsening asthma or COPD:

    Decreasing effectiveness of inhaled, short-acting beta2-agonists

    Need for more inhalations than usual of inhaled, short-acting beta2-agonists

    Significant decrease in PEF or lung function as outlined by the physician

    Use of 4 or more inhalations per day of a short-acting beta2-agonist for 2 or more days consecutively

    Use of more than 1 canister (200 inhalations per canister) of an inhaled, short-acting beta2-agonist in an 8-week period.

    7. SEREVENT DISKUS should not be used as a substitute for oral or inhaled corticosteroids. The dosage of these medications should
    not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating
    treatment with SEREVENT DISKUS.

    8. Patients should be cautioned regarding adverse effects associated with beta2-agonists, such as palpitations, chest pain, rapid
    heart rate, tremor, or nervousness.

    9. When patients are prescribed SEREVENT DISKUS, other medications for asthma and COPD should be used only as directed by the
    physician.

    10. SEREVENT DISKUS should not be used with a spacer device.

    11. Patients who are pregnant or nursing should contact the physician about the use of SEREVENT DISKUS.

    12. Effective and safe use of SEREVENT DISKUS includes an understanding of the way that it should be used:

    Never exhale into the DISKUS.

    Never attempt to take the DISKUS apart.

    Always activate and use the DISKUS in a level, horizontal position.

    Never wash the mouthpiece or any part of the DISKUS. KEEP IT DRY.

    Always keep the DISKUS in a dry place.

    Discard 6 weeks after removal from the moisture-protective foil overwrap pouch or after all blisters have been used (when the
    dose indicator reads "0" ), whichever comes first.

    13. For the proper use of SEREVENT DISKUS and to attain maximum benefit, the patient should read and follow carefully the Patient's
    Instructions for Use accompanying the product.

    Arial Atto interessato organismi

    Gli esseri umani e altri mammiferi